RPTX - Repare Therapeutics Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 499.17M
Enterprise value 190.08M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)3.63
Price/book (mrq)1.99
Enterprise value/revenue 1.39
Enterprise value/EBITDA -10.71

Trading information

Stock price history

Beta (5Y monthly) 0.07
52-week change 3-18.38%
S&P500 52-week change 36.21%
52-week high 318.68
52-week low 38.53
50-day moving average 39.80
200-day moving average 312.31

Share statistics

Avg vol (3-month) 3102k
Avg vol (10-day) 3124.85k
Shares outstanding 542.09M
Implied shares outstanding 6N/A
Float 816.62M
% held by insiders 16.19%
% held by institutions 189.36%
Shares short (14 May 2023) 41.29M
Short ratio (14 May 2023) 414.55
Short % of float (14 May 2023) 45.18%
Short % of shares outstanding (14 May 2023) 43.06%
Shares short (prior month 13 Apr 2023) 41.55M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023

Profitability

Profit margin -21.32%
Operating margin (ttm)-14.33%

Management effectiveness

Return on assets (ttm)-3.65%
Return on equity (ttm)-11.47%

Income statement

Revenue (ttm)137.1M
Revenue per share (ttm)3.27
Quarterly revenue growth (yoy)1,291.70%
Gross profit (ttm)15.11M
EBITDA -17.75M
Net income avi to common (ttm)-29.23M
Diluted EPS (ttm)-0.76
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)314.12M
Total cash per share (mrq)7.46
Total debt (mrq)5.04M
Total debt/equity (mrq)2.01
Current ratio (mrq)4.02
Book value per share (mrq)5.97

Cash flow statement

Operating cash flow (ttm)-1.46M
Levered free cash flow (ttm)52.65M